Experts discuss the necessity of ESR1 mutation testing when considering treatment with elacestrant in patients with estrogen receptor–positive (ER+)/HER2-negative (HER2–) metastatic breast cancer and ...
Integrating HER2-directed therapies into NSCLC decision-making requires adapting protocols and ensuring timely updates as new therapies emerge. Streamlined processes and enhanced communication among ...
Assessing mutagenic effects in the germ line is essential for understanding reproductive risks, heritable genetic disorders and long-term population health. Transgenic models, especially rodents ...
Dr. Angie DeMichele and Dr. Lynn Henry present the latest rapid recommendation impacting two ASCO guidelines. This update focuses on testing for ESR1 mutations in patients with hormone ...
We offer targeted detection of a previously characterized mutation within the family. From a fresh EDTA blood sample, DNA is extracted directly and the target region is amplified and directly ...
Blood-based circulating tumor DNA (ctDNA) testing has proven to be insufficient for detecting KRAS mutations in patients with low-grade serous ovarian cancer (LGSOC), according to a study. The ...
Knowledge of mutational patterns has expanded significantly, but linking these patterns to specific molecular mechanisms or sources of endogenous DNA damage remains challenging. Translesion synthesis ...
Scientists at the Victor Chang Cardiac Research Institute have developed a world-first individualised risk prediction tool for people suffering from a type of heart arrhythmia that can cause sudden ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results